TKI targeted therapy for nsclc with ALK ROS1 NTRK mutations surveying safety data sequencing and resistance
TKI Targeted Therapy for NSCLC With ALK, ROS1 & NTRK Mutations: Surveying Safety Data, Sequencing and Resistance. SEE VIDEO
VuMedi
Author: Susan Arnold